Improved Octreotide-Based Radiotherapy Achieves 80% Survival in Neuroendocrine Tumor Mouse Model

New SSTR2-targeted peptides were designed with a modified cyclization technique, lead-specific chelator (PSC), and PEG linkers. Binding affinity and cellular uptake were tested in AR42J pancreatic tumor cells (SSTR2+). Biodistribution and imaging were assessed in AR42J tumor xenograft mice using lead-203. Therapeutic efficacy was evaluated with lead-212 (alpha particle therapy) in the same mouse model, including dose-response and fractionated dosing studies.

Neuroendocrine tumors are often treated with peptide receptor radionuclide therapy (PRRT) using beta-emitting isotopes, but alpha particles are more potent at killing cancer cells. This study demonstrates that structurally optimized octreotide peptides can effectively deliver alpha-emitting lead-212 to tumors, potentially providing more effective treatment than current beta-particle approaches for neuroendocrine cancers.

Peptide receptor radionuclide therapy (PRRT) with Lutathera (lutetium-177 DOTATATE) is already an approved treatment for neuroendocrine tumors. The shift toward alpha-emitting isotopes like lead-212, which cause more concentrated DNA damage in tumor cells, represents the next frontier. This study demonstrates that peptide engineering can optimize these next-generation radiopharmaceuticals for superior performance.

This was a preclinical study using a subcutaneous xenograft mouse model, which doesn't fully replicate human neuroendocrine tumors. The AR42J cell line may not represent the diversity of human NETs. Long-term toxicity of alpha particle therapy was not fully assessed. Translation to humans requires addressing differences in pharmacokinetics, radiation dosimetry, and tumor biology. Lead-212's 10.6-hour half-life presents manufacturing and logistics challenges.